Effect of the Methylene Blue drug in patients with Severe Infectio

Phase 2

Recruiting

• Conditions: nspecified septicemia, Septic shock; R57.9; C23.550.835

• Registration Number: RBR-96584w4
• Lead Sponsor: Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-12-06
• Study Completion: 2022-11-01
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Aged between 18 and 85 years; of both sexes; who were victims of septic shock of any origin in the first 72 hours of evolution; in use of noradrenaline larger dose 0.3 mcg/kg/min; vasopressin dose 0,05 ui/min; and using mechanical ventilation

Exclusion Criteria

Pregnant patients (negative pregnancy test in female patients of childbearing age); in use of serotonergic agents; previous septic shock in the same hospital; use of immunosuppressive therapy; CD4 smaller 200 cells/mm3; neutrophils smaller 500 mm3; palliative care; imminent or inevitable death during hospitalization

Study & Design

• Study Type: Intervention
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A reduction in the dose of norepinephrine and vasopressin is expected in a patient with septic shock in the standard treatment plus methylene blue group compared to the standard treatment group.

Secondary Outcome Measures

Name	Time	Method
Mortality reduction within 30 days